{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:04:04Z","timestamp":1786122244346,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study estimated the number and percentage of Medicare fee\u2010for\u2010service (FFS) beneficiaries who use GLP\u20101 RAs, are currently eligible or could become eligible if ongoing\u2010trial indications receive approval and coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used Medicare enrolment and claims data, representing 100% of Medicare FFS beneficiaries. The study period was 1 January 2023 through 31 December 2024. Patients aged \u2265\u200918\u2009years at the beginning of the study period who were alive and continuously enrolled in Medicare FFS Parts A, B and D for all 24\u2009months were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among Medicare FFS beneficiaries with Part D (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916\u2009474\u2009786), 6.2% had GLP\u20101 RAs. Overall, 35.1% had a currently covered GLP\u20101 indication (Type 2 diabetes, established cardiovascular disease with overweight\/obesity, obstructive sleep apnoea with obesity or metabolic dysfunction\u2010associated steatohepatitis). Among beneficiaries with a condition currently covered by Medicare, only 16.5% had a claim for a GLP\u20101 RA. In total, 76.9% had \u2265\u20091 currently covered or potential future indication. An estimated 1.2 million (7.0%) had obesity alone and were ineligible under current policy. If Medicare covered heart failure with preserved ejection fraction, chronic kidney disease, psoriasis and\/or knee osteoarthritis, 35% of these currently ineligible beneficiaries (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009407\u2009085) could gain access.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coverage via secondary conditions may broaden potential access to anti\u2010obesity medications for Medicare FFS patients, but eligibility alone may not translate into actual treatment uptake unless affordability and other barriers are addressed. Further studies should quantify net benefits and costs of AOMs in Medicare FFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71033","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:19:49Z","timestamp":1782400789000},"page":"8398-8406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Obesity and Related Conditions and\n                    <scp>GLP<\/scp>\n                    \u20101 Use in Medicare Fee\u2010for\u2010Service Beneficiaries"],"prefix":"10.1111","volume":"28","author":[{"given":"Sonia","family":"Kim","sequence":"first","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Barthel","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Smurzynski","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"MacEwan","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz273"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:106273"},{"key":"e_1_2_10_4_1","unstructured":"Centers for Medicare & Medicaid Services (CMS) \u201cData Snapshot: Obesity and Medicare Beneficiaries \u201d2023 https:\/\/www.cms.gov\/files\/document\/omh\u2010datasnapshot\u2010obesity.pdf."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.2.179"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1361915"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010023\u201001376\u20104"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010024\u201001150\u20109"},{"key":"e_1_2_10_9_1","unstructured":"U.S. Food and Drug Administration (FDA) \u201cWegovy (Semaglutide) Injection for Subcutaneous Use\u2014Prescribing Information \u201d2021 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215256s000lbl.pdf."},{"key":"e_1_2_10_10_1","unstructured":"U.S. Food and Drug Administration (FDA) \u201cFDA Approves Weight Management Drug for Patients Aged 12 and Older \u201d2020 https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010weight\u2010management\u2010drug\u2010patients\u2010aged\u201012\u2010and\u2010older."},{"key":"e_1_2_10_11_1","unstructured":"U.S. Food and Drug Administration (FDA) \u201cFDA Approves New Medication for Chronic Weight Management \u201d2023 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010medication\u2010chronic\u2010weight\u2010management."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403664"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929\u2010024\u201001090\u2010x"},{"key":"e_1_2_10_18_1","unstructured":"Centers for Medicare & Medicaid Services (CMS) \u201cPart D Drugs\/Part D Excluded Drugs \u201daccessed July 8 2025 https:\/\/www.cms.gov\/medicare\/prescription\u2010drug\u2010coverage\/prescriptiondrugcovcontra\/downloads\/partddrugspartdexcludeddrugs.pdf."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010024\u201001473\u2010y"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd24\u20100115"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.07.004"},{"key":"e_1_2_10_22_1","unstructured":"Congressional Budget Office \u201cHow Would Authorizing Medicare to Cover Anti\u2010Obesity Medications Affect the Federal Budget? \u201d2024 https:\/\/www.cbo.gov\/system\/files\/2024\u201010\/60441\u2010medicare\u2010coverage\u2010obesity.pdf."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00356"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.07.007"},{"key":"e_1_2_10_26_1","unstructured":"A. S.Ward B.Tysinger P.Nguyen D. P.Goldman andD.Lakdawalla Benefits of Medicare Coverage for Weight Loss Drugs Schaeffer Center White Paper Series (USC Schaeffer 2023)."},{"key":"e_1_2_10_27_1","unstructured":"Centers for Medicare & Medicaid Services \u201cHHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors \u201d2025 https:\/\/www.cms.gov\/newsroom\/press\u2010releases\/hhs\u2010announces\u201015\u2010additional\u2010drugs\u2010selected\u2010medicare\u2010drug\u2010price\u2010negotiations\u2010continued\u2010effort\u2010lower."},{"key":"e_1_2_10_28_1","unstructured":"AHIP \u201cNew Analysis Shows Medicare Advantage Outperforms Fee\u2010for\u2010Service Medicare in Improving Patient Outcomes Delivering Care at a Lower Cost \u201d2025 https:\/\/www.ahip.org\/news\/articles\/new\u2010analysis\u2010shows\u2010medicare\u2010advantage\u2010outperforms\u2010fee\u2010for\u2010service\u2010medicare\u2010in\u2010improving\u2010patient\u2010outcomes\u2010delivering\u2010care\u2010at\u2010a\u2010lower\u2010cost."},{"key":"e_1_2_10_29_1","unstructured":"Better Medicare Alliance \u201cState of Medicare Advantage: The Latest Trends and Data for 2024 \u201d2024 https:\/\/bettermedicarealliance.org\/blog\u2010posts\/state\u2010of\u2010medicare\u2010advantage\u2010the\u2010latest\u2010trends\u2010and\u2010data\u2010for\u20102024\/."},{"key":"e_1_2_10_30_1","unstructured":"Centers for Medicare & Medicaid Services (CMS) \u201cMedicare Monthly Enrollment \u201d2026 https:\/\/data.cms.gov\/summary\u2010statistics\u2010on\u2010beneficiary\u2010enrollment\/medicare\u2010and\u2010medicaid\u2010reports\/medicare\u2010monthly\u2010enrollment."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2017.0092"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11111529"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:51:29Z","timestamp":1786092689000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.71033"],"URL":"https:\/\/doi.org\/10.1111\/dom.71033","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}